3. Induction of ␦-aminolevulinic acid synthetase (ALA-S) activity was found, as expected, in animals receiving AIA and also in animals treated with AIA plus anaesthesia, but no change in the activity of either porphobilinogenase (PBGase) or porphobilinogen deaminase (PBG-D) activities was detected in these two groups of animals. An additional increase in haem destruction was observed in the AIA plus isoflurane-treated group. When mice were injected with imidazol alone or in combination with the anaesthetics, ALA-S activity was increased 50-90% in all groups, but again no change in PBGase or PBG-D activity was observed. Haem oxygenase was diminished in mice receiving imidazole and anaesthesia.
INTRODUCTION
The porphyrias are genetically transmitted disorders of haem metabolism. Their clinical expression may be influenced by external factors as well as by endogenous processes. Thus, in the acute types of porphyria, neuropsychiatric symptoms are precipitated by exposure to cytochrome P450 (CYP)-inducing agents and by conditions such as hormonal changes, infection and low caloric intake. 1, 2 A common denominator for the acute porphyrias during the attack is the overproduction of the porphyrin precursor ␦-aminolevulinic acid (ALA). Therefore, it seems plausible to assume that the reason for the varying susceptibility to clinical manifestations of the disorder may be found in differences in metabolic processes determining the rate of ALA generation at given degrees of induction of the rate-limiting enzyme in haem synthesis, namely ␦-aminolevulinic acid synthetase (ALA-S). 3 The same drugs that induce ALA-S also induce the synthesis of several members of the microsomal CYP family. 4 Considering that the concentration of CYP in hepatocytes is relatively high, the induction of this mixed-function oxidase will deplete the free haem pool and, so, increase the activity of ALA-S. 5 Porphyrias present special anaesthetic challenges, including pre-operative assessment of a patient with acute abdominal pain, intra-operative management of a known porphyria and respiratory and cardiovascular management of acute porphyric crisis. 6 Enflurane (Ethrane; Abbott Laboratories Argentine SA, Sarmiento, Argentina; 2-chloro-1,1,2-trifluorethyldifluormethylether) and isoflurane (Forane; Abbott Laboratories Argentine SA, 1-chloro-2,2,2-trifluormethyldifluormethylether) are volatile anaesthetics commonly used in medical practice. The toxicity of these anaesthetics is closely related to their metabolism catalysed by hepatic CYP. 7 Allylisopropylacetamide (AIA), a known porphyrinogenic xenobiotic, causes destruction of the cytochrome haem group, thus requiring new haem synthesis with consequent ALA-S induction. 8, 9 Imidazol is a powerful CYP inductor; pretreatment of rabbits with this xenobiotic resulted in a two-fold increase in hepatic microsomal CYP content. 10, 11 Hoffman et al 12 observed a 250% increase in enflurane metabolism in rabbits treated with imidazole.
Acute and chronic administration of enflurane and isoflurane has been shown to produce marked alterations in haem metabolism, confirming the porphyrinogenic properties of these drugs. 13 We have demonstrated that enflurane 14 and isoflurane 15 alter haem metabolism in Swiss mice when the anaesthetics were administered in a single dose of 2 mL/kg and the results tested 20 min later. Strain and sex differences in the effects of enflurane and isoflurane have also been reported. 16 Alterations in haem metabolism produced by chronic enflurane anaesthesia may be directly related to increased CYP levels, which eventually lead to ALA-S induction. In contrast, chronic isoflurane anaesthesia may induce ALA-S through an alternative mechanism, which appears either not to involve CYP or to be through specific variations in CYP2E1. 17 The aim of the present study was to investigate the effects of enflurane and isoflurane on haem metabolism and its regulation in mice in different metabolic states, such as induction and depression of CYP produced by imidazole and AIA, respectively. The focus of the present study points out the possibility that raising or lowering CYP levels in the liver may change the metabolism of volatile anaesthetics and, thus, influence the effects of these agents on haem metabolism.
In the present study, we have measured the activity of ALA-S and the enzyme system porphobilinogenase (PBGase) and porphobilinogen deaminase (PBG-D) to evaluate any possible alteration in haem biosynthesis, as well as the activity of haem oxygenase (haem-ox), the first enzyme involved in the breakdown of haem, and rhodanese, the enzyme responsible for the degradation of cystine trisulphide, which has been proposed as an activator of ALA-S.
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METHODS
Enflurane and isoflurane were obtained from Abbott Laboratories (Sarmiento, Argentina). All other chemicals used were reagent grade and were obtained from Sigma Chemical Co. (St Louis, MO, USA).
Animals
Albino male adult CF1 mice (six animals/group), weighing 25-30 g, were maintained under controlled conditions and were allowed free access to food (Purina 3; Asociación de Cooperativas Argentinas, San Nicolás, Buenos Aires, Argentina) and water. Animals received humane care and were treated in accordance with the guidelines established by the Animal Care and Use Committee of the Argentine Association of Specialists in Laboratory Animals (AADEALC). 
Treatments
Enflurane or isoflurane
Imidazole
Animals received 400 mg/kg, i.p., imidazole over 4 days. Twenty-four hours after the last injection of imidazole, mice were injected with the anaesthetics and were killed 20 min later.
Control animals and animals receiving AIA or imidazole alone were injected with corn oil, used as vehicle for the anaesthetics, and were killed at the same time as the group receiving enflurane or isoflurane only.
Methods of analysis
Control and treated mice were always killed at the same time of the day, under ether anaesthesia by cardiac puncture and bled. Tissue (liver and whole blood) preparations were obtained and enzyme (ALA-S, PBGase, PBG-D, haem-ox and rhodanese) measurements were performed as described previously.
14 Liver assays were performed in whole homogenates for ALA-S or in the cytosolic fraction obtained after centrifugation at 18 000 g for other enzyme activities. The levels of CYP were determined in liver microsomes using the method of Omura and Sato. 19 Protein concentrations were estimated by the method of Lowry et al. 20 One enzyme unit was defined as the amount of enzyme that catalysed the formation of 1 nmol product under the standard incubation conditions. Specific activity was expressed as enzymic units per mg protein.
Statistical analysis
Data are shown as the meanϮSD for each variable for each group and values were compared using the Newman-Keuls' test. The significance of differences between groups was analysed using analysis of variance (ANOVA) and P < 0.05 was regarded as significant. Fig. 1 Effects of the administration of enflurane and isoflurane on liver haem metabolism and its regulation. (ᮀ), control; ( ), enflurane; (), isoflurane. Mice received one dose of 1 mL/kg enflurane or isoflurane and were killed 20 min later. Data are the meanϮSD of at least six animals. *P < 0.01 for comparisons between treated and control groups. Other experimental details are as described in the text. ALA-S, ␦-aminolevulinic acid synthetase; PBGase, porphobilinogenase; PGB-D, porphobilinogen deaminase; haem-ox; heam oxygenase; CYP, cytochrome P450; sp. act., specific activity. Fig. 2 Effects of the administration of enflurane and isoflurane to imidazole-treated animals on liver haem metabolism and its regulation. (ᮀ), control; ( ), imidazole; (), imidazole + enflurane; ( ), imidazole + isoflurane. Mice received 400 mg/kg, i.p., imidazole over 4 days; 24 h after the last injection of imidazole, they were injected with the anaesthetics and were killed 20 min after the administration of the anaesthetic. *P < 0.01 for comparisons between treated and control groups; † P < 0.05, ‡ P < 0.01 for comparisons between mice treated with imidazole and imidazole plus anaesthetic. Other experimental details or conditions are as given in Fig. 1 or the text. ALA-S, ␦-aminolevulinic acid synthetase; PBGase, porphobilinogenase; PGB-D, porphobilinogen deaminase; haem-ox; heam oxygenase; CYP, cytochrome P450; sp. act., specific activity.
RESULTS
Effect of anaesthetics
When animals received the anaesthetics alone, no significant changes in any of the liver parameters assayed were observed, except a 118% (P < 0.01) induction of haem-ox activity after isoflurane administration (Fig. 1) . No alterations were detected in blood parameters (data not shown).
Effects of anaesthetics in imidazole-treated mice
Results obtained in the livers of mice with CYP induction produced by imidazole administration are shown in Fig. 2 .
The activity of ALA-S was increased 84% (P < 0.01) in animals treated with imidazole. Enzyme activity was induced by approximately 90 and 53% (both P < 0.01) by imidazole + enflurane or imidazole + isoflurane, respectively. The magnitude of the induction was not statistically different between the different groups.
The activity of PBGase and PBG-D was not modified in any group.
Imidazole administration alone produced no changes in haem-ox activity. However, mice treated with a combination of this xenobiotic and an anaesthetic showed a 50-85% (P < 0.01) inhibition of enzyme activity. Statistical studies showed a statistically significant difference (P < 0.01) between the effects of imidazole alone and in combination with the anaesthetics.
Rhodanese activity was reduced 50-60% (P < 0.01) in animals treated with imidazole or imidazole + enflurane and reduced 40% (P < 0.01) when isoflurane was the anaesthetic injected instead of enflurane.
The induction of CYP levels caused by imidazole (80%; P < 0.01) was abolished by the anaesthesia and the difference in CYP levels in imidazole-and imidazole + anaesthetic-treated groups was statistically significant (P < 0.01).
Blood activity of PBGase, PBG-D and rhodanese (data not shown) was unchanged in all groups studied.
Effects of anaesthetics in AIA-treated mice
Results obtained in mice with CYP depletion caused by AIA administration are shown in Fig. 3 .
Liver ALA-S activity was increased approximately 190% (P < 0.01) in animals treated with AIA or AIA + enflurane and was increased 120% (P < 0.05) in mice receiving AIA + isoflurane (Fig.  3a ). The differences between the level of induction in the different groups were not statistically significant.
Both liver (Fig. 3a) and blood (Fig. 3b) PBGase and PBG-D activities were unchanged in all groups.
Liver haem-ox activity was enhanced 240% (P < 0.05) by AIA administration. When animals received AIA plus enflurane or isoflurane, the induction of haem-ox activity was 200 (P < 0.05) and 430% (both P < 0.01), respectively (Fig. 3a) . There was a significant difference observed between the AIA-and AIA plus isoflurane-treated groups.
Liver rhodanese activity (Fig. 3a) was reduced by 40 and 83% (both P < 0.05) in mice treated with AIA or AIA + isoflurane, respectively, while the administration of AIA + enflurane had no effect on the activity of this enzyme. A similar profile was found for the activity of the enzyme in the blood (Fig. 3b ) in mice receiving AIA or AIA + enflurane, without any changes in enzyme activity seen after the administration of AIA + isoflurane. Statistical studies of differences between groups treated with AIA and AIA + isoflurane in the liver or AIA and AIA + enflurane in the blood revealed no differences, but when groups in which rhodanese activity was unchanged were compared with groups AIA 16 h prior to the injection of the anaesthetics and were killed 20 min after administration of the anaesthetic. † P < 0.05, *P < 0.01 for comparisons between treated and control groups; ‡ P < 0.05 for comparisons between animals treated with AIA alone and AIA plus anaesthetics. Other experimental details or conditions are as given in Fig. 1 or the text. ALA-S, ␦-aminolevulinic acid synthetase; PBGase, porphobilinogenase; PGB-D, porphobilinogen deaminase; haem-ox; heam oxygenase; CYP, cytochrome P450; sp. act., specific activity.
receiving only AIA the differences were statistically significant (P < 0.05).
The marked reduction in CYP levels (55%; P < 0.05) caused by AIA alone (Fig. 3a) was also observed after the administration of enflurane (64%; P < 0.05) and isoflurane (90%; P < 0.05). These differences are not of statistical significance.
DISCUSSION
The effect of fluorinated ether anaesthetics, such as enflurane and isoflurane, in mice on haem metabolism and regulation was investigated in the following different metabolic states: (i) induction of CYP by imidazole; and (ii) depression of CYP by AIA.
Oxidative metabolism represents a major route of elimination of many drugs and, because many drugs can compete for the same enzyme, inhibition of CYP enzymes is one of the main reasons for drug interactions. 21 Allylisopropylacetamide, an olefinic derivative, is a classic suicide substrate of CYP. This compound is now recognized as an effective haem-alkylating inactivator of rat CYP2B1 and CYP3A1, while CYP2C6 and CYP2CII are less susceptible. 22 In AIA-treated animals, the known marked induction of ALA-S was observed in animals receiving this drug and anaesthesia, but no changes were found for either PBGase and PBG-D activity, the enzymes specifically altered in acute intermittent porphyria. The activity of haem-ox was induced above 100% in animals treated with AIA and the anaesthetics, indicating increased haem destruction.
The induction of CYP is a slow regulatory process that can reduce drug concentrations in plasma and may compromise the efficacy of the drug in a time-dependent manner. 21 In drug therapy, there are two major concerns related to CYP induction. First, induction will result in a reduction of the pharmacological effects caused by increased drug metabolism. Second, induction may create an undesirable imbalance between 'toxification' and 'detoxification'. Depending on the delicate balance between detoxification and activation, induction can be a beneficial or harmful response. 21 In the present study, in animals treated with imidazole, ALA-S activity remained high when mice also received anaesthesia. No changes in activity were detected in liver and blood PBGase and PBG-D. The activity of haem-ox was diminished by the combination of imidazole and the anaesthetics.
No explanation can be given about the different effects of isoflurane on haem-ox when CYP levels were either unchanged or decreased or increased. Animal data have demonstrated that there are considerable differences among the anaesthetics in their responses to enzyme induction following pretreatment with specific drugs. 23 To this end, we have previously observed that induction of haem-ox provoked by cobalt treatment was reversed by isoflurane administration without further alterations in CYP levels. 24 In contrast, haem-ox enhancement found in chronically alcoholized animals persisted after isoflurane anaesthesia, with a concomitant increase in CYP levels. 25, 26 In conclusion, neither enflurane nor isoflurane produced further disturbances in haem metabolism than those due to the sole action of AIA or imidazole. However, in animals treated with AIA, its combination with isoflurane led to a significant induction in haem-ox activity, indicating enhanced degradation of haem. In contrast, anaesthetic administration to the imidazole-treated group significantly reduced this enzyme activity. The induction of ALA-S by AIA or imidazole and also after anaesthetic administration has both fundamental and clinical relevance because ALA-S induction is not only responsible for adapting haem synthesis to rapid changes in haem demand but also because it plays a key role in the genetic disorders leading to the hepatic porphyrias. 27 The inverse relationship observed between the activity of rhodanese and ALA-S confirms, once more, the involvement of this sulphur metabolism enzyme in the regulation of haem synthesis in mammals. 28 
